Business Context and Reporting Period
Company: Phathom Pharmaceuticals, Inc. (PHAT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Event: Completion of patient enrollment in the Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA (vonoprazan) in the treatment of eosinophilic esophagitis (EoE).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Progress
- Enrollment Complete: The pHalcon-EoE-201 study has enrolled 95 patients across 41 U.S. sites.
- Study Design: A two-part, randomized, double-blind, placebo-controlled Phase 2 study.
- Part 1: 95 adults randomized to receive VOQUEZNA 20 mg or placebo once daily for 12 weeks.
- Part 2: A 12-week extension phase where all participants receive VOQUEZNA 20 mg once daily.
- Timeline: Topline results are anticipated in the fourth quarter of 2026.
Outlook, Management Commentary, and Risks
Strategic Outlook: If the study generates positive results, Phathom expects to discuss future development plans with the FDA, including a potential pediatric evaluation. A successful pediatric program could support an extension of regulatory exclusivity for VOQUEZNA.
Risks and Contingencies:
- Results may be negative or mixed, insufficient to advance the program.
- Even with positive results, the company may decide not to advance the EoE program or may not agree with the FDA on a pediatric program.
- Pediatric studies may not meet requirements or timelines for regulatory exclusivity extensions.
- Success may be impacted by safety issues, competition, or technical challenges.
- Regulatory authorities may not approve VOQUEZNA for EoE even if studies are successful.
- Future cash needs may alter development plans.
Investor Verification Checklist
- Verify the anticipated Q4 2026 timeline for topline results of the pHalcon-EoE-201 study.
- Monitor FDA discussions regarding potential pediatric evaluation and regulatory exclusivity extensions.
- Review the company's cash position in subsequent filings (10-Q/10-K) to assess ability to fund future development phases.
- Track any updates on safety or tolerability data from the 95 enrolled patients.